Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 55 of 6351
-
Can a school program turn the tide on teen suicide?
Prevention OngoingThe aim of this study is to evaluate the acceptability, feasibility, and fidelity of implementing a stratified care intervention for adolescents with suicidal ideation and depressive symptoms, and to preliminarily explore its effectiveness in reducing suicidal ideation and depres…
Sponsor: Universidad de los Andes, Chile • Aim: Prevention
Last updated Aug 23, 2026 00:00 UTC
-
New drug cocktail aims to stop liver cancer from coming back after surgery
Disease control Recruiting nowThis is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
Phase 3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Phase 3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
Vaccine Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Phase 3 • Sponsor: Invivyd, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 14:00 UTC
-
New hybrid stroke unit aims to cut lifesaving treatment time
Disease control Not yet recruitingThis study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic strok…
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
Disease control Not yet recruitingThis study is a single-arm, single-center prospective clinical study that will evaluate the clinical feasibility and efficacy of immunotherapy combined with chemotherapy in the neoadjuvant treatment of ovarian cancer, in order to explore the progression-free survival of the study…
Phase 2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill plus chemo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Phase 3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can antivirals tame a deadly Tick-Borne virus?
Disease control Recruiting nowCCHF has a wide geographical distribution with cases mainly occurring in Asia, the Middle East, South-Eastern Europe and Africa. Since its emergence in 2002, Turkiye has been the epicentre of activity worldwide reporting up to more than 1000 cases annually. CCHF case management r…
Phase 2 • Sponsor: Liverpool School of Tropical Medicine • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Hope for stargardt patients: new drug aims to slow blindness
Disease control Recruiting nowThis study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
Phase 3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Eye drop breakthrough: nerve growth factor heals corneal wounds in phase 3 trial
Cure Recruiting nowThis is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of…
Phase 3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Promising new drug combo takes on advanced lung cancer in major trial
Disease control Not yet recruitingThis study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for patients with PD-L1-Positive locally advanced or metastat…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a vitamin boost Babies' brains before birth?
Prevention Recruiting nowThiamine (vitamin B1) is an important nutrient needed for energy metabolism, brain development, and overall health. However, low thiamine intake is a concern in countries where white rice is the main staple since it contains little thiamine. If pregnant or breastfeeding women do …
Sponsor: Mount Saint Vincent University • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
Blood test could spare stomach cancer patients from unnecessary chemo
Disease control Not yet recruitingFor locally advanced gastric adenocarcinoma/esophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including chemotherapy, immunotherapy, etc.). This approach involv…
Phase 3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough lung cancer: experimental drug takes on KRAS mutation
Disease control Not yet recruitingThe study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Liver transplant may beat surgery for certain colorectal cancer patients
Disease control Recruiting nowThe TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and/or ablation) in patients with initially unresectable colorectal liver metastases (CRLM) converted to resectabilit…
Sponsor: Niguarda Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New model aims to cure hepatitis c in homeless drug users
Cure Recruiting nowThe objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) …
Sponsor: University of Washington • Aim: Cure
Last updated Jun 27, 2026 14:02 UTC
-
Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
Disease control Stopped earlyThe purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take aim at leukemia that evades standard therapy
Disease control Stopped earlyThis study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse af…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cervical cancer
Disease control Stopped earlyThe primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo aims to fight resistant lung cancer
Disease control Not yet recruitingThis study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC. The Phase III study is planned to enroll approximately 680 participants, who will be randomized in a 1:1 ratio into the followin…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC